Bioporto A/S
CSE:BIOPOR

Watchlist Manager
Bioporto A/S Logo
Bioporto A/S
CSE:BIOPOR
Watchlist
Price: 1.624 DKK -2.4% Market Closed
Market Cap: 697.8m DKK
Have any thoughts about
Bioporto A/S?
Write Note

Intrinsic Value

BIOPOR's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one BIOPOR stock under the Base Case scenario is 1.257 DKK. Compared to the current market price of 1.624 DKK, Bioporto A/S is Overvalued by 23%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BIOPOR Intrinsic Value
1.257 DKK
Overvaluation 23%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Bioporto A/S

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for BIOPOR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about BIOPOR?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Bioporto A/S

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Bioporto A/S

Provide an overview of the primary business activities
of Bioporto A/S.

What unique competitive advantages
does Bioporto A/S hold over its rivals?

What risks and challenges
does Bioporto A/S face in the near future?

Summarize the latest earnings call
of Bioporto A/S.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Bioporto A/S.

Provide P/S
for Bioporto A/S.

Provide P/E
for Bioporto A/S.

Provide P/OCF
for Bioporto A/S.

Provide P/FCFE
for Bioporto A/S.

Provide P/B
for Bioporto A/S.

Provide EV/S
for Bioporto A/S.

Provide EV/GP
for Bioporto A/S.

Provide EV/EBITDA
for Bioporto A/S.

Provide EV/EBIT
for Bioporto A/S.

Provide EV/OCF
for Bioporto A/S.

Provide EV/FCFF
for Bioporto A/S.

Provide EV/IC
for Bioporto A/S.

Show me price targets
for Bioporto A/S made by professional analysts.

What are the Revenue projections
for Bioporto A/S?

How accurate were the past Revenue estimates
for Bioporto A/S?

What are the Net Income projections
for Bioporto A/S?

How accurate were the past Net Income estimates
for Bioporto A/S?

What are the EPS projections
for Bioporto A/S?

How accurate were the past EPS estimates
for Bioporto A/S?

What are the EBIT projections
for Bioporto A/S?

How accurate were the past EBIT estimates
for Bioporto A/S?

Compare the revenue forecasts
for Bioporto A/S with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Bioporto A/S and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Bioporto A/S against its competitors.

Analyze the profit margins
(gross, operating, and net) of Bioporto A/S compared to its peers.

Compare the P/E ratios
of Bioporto A/S against its peers.

Discuss the investment returns and shareholder value creation
comparing Bioporto A/S with its peers.

Analyze the financial leverage
of Bioporto A/S compared to its main competitors.

Show all profitability ratios
for Bioporto A/S.

Provide ROE
for Bioporto A/S.

Provide ROA
for Bioporto A/S.

Provide ROIC
for Bioporto A/S.

Provide ROCE
for Bioporto A/S.

Provide Gross Margin
for Bioporto A/S.

Provide Operating Margin
for Bioporto A/S.

Provide Net Margin
for Bioporto A/S.

Provide FCF Margin
for Bioporto A/S.

Show all solvency ratios
for Bioporto A/S.

Provide D/E Ratio
for Bioporto A/S.

Provide D/A Ratio
for Bioporto A/S.

Provide Interest Coverage Ratio
for Bioporto A/S.

Provide Altman Z-Score Ratio
for Bioporto A/S.

Provide Quick Ratio
for Bioporto A/S.

Provide Current Ratio
for Bioporto A/S.

Provide Cash Ratio
for Bioporto A/S.

What is the historical Revenue growth
over the last 5 years for Bioporto A/S?

What is the historical Net Income growth
over the last 5 years for Bioporto A/S?

What is the current Free Cash Flow
of Bioporto A/S?

Discuss the annual earnings per share (EPS)
trend over the past five years for Bioporto A/S.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Bioporto A/S

Current Assets 123.9m
Cash & Short-Term Investments 103.9m
Receivables 13.4m
Other Current Assets 6.6m
Non-Current Assets 7.7m
Long-Term Investments 1.3m
PP&E 1.1m
Intangibles 346k
Other Non-Current Assets 4.9m
Current Liabilities 23.2m
Accounts Payable 5.5m
Accrued Liabilities 15.4m
Other Current Liabilities 2.3m
Non-Current Liabilities 3.5m
Long-Term Debt 3.5m
Efficiency

Earnings Waterfall
Bioporto A/S

Revenue
33.8m DKK
Cost of Revenue
-9.8m DKK
Gross Profit
24.1m DKK
Operating Expenses
-82m DKK
Operating Income
-57.9m DKK
Other Expenses
7.9m DKK
Net Income
-50m DKK

Free Cash Flow Analysis
Bioporto A/S

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

BIOPOR Profitability Score
Profitability Due Diligence

Bioporto A/S's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
ROE is Increasing
Positive 3-Years Revenue Growth
Positive 1-Year Revenue Growth
25/100
Profitability
Score

Bioporto A/S's profitability score is 25/100. The higher the profitability score, the more profitable the company is.

BIOPOR Solvency Score
Solvency Due Diligence

Bioporto A/S's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
99/100
Solvency
Score

Bioporto A/S's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BIOPOR Price Targets Summary
Bioporto A/S

Wall Street analysts forecast BIOPOR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BIOPOR is 3.06 DKK with a low forecast of 3.03 DKK and a high forecast of 3.15 DKK.

Lowest
Price Target
3.03 DKK
87% Upside
Average
Price Target
3.06 DKK
88% Upside
Highest
Price Target
3.15 DKK
94% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for BIOPOR?

Click here to dive deeper.

Dividends

Bioporto A/S
does not pay dividends
Shareholder Yield

Current shareholder yield for BIOPOR is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Bioporto A/S Logo
Bioporto A/S

Country

Denmark

Industry

Biotechnology

Market Cap

697.8m DKK

Dividend Yield

0%

Description

Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.

Contact

Hellerup
Tuborg Havnevej 15, St.
+4545290000.0
www.bioporto.com

IPO

1985-01-02

Employees

29

Officers

Chief Executive Officer
Mr. Peter Moerch Eriksen B.B.A., BBA
Executive VP & CFO
Mr. Niels Hoey Nielsen
Chief Scientific Officer
Dr. Lars Otto Uttenthal
Executive VP & Chief Legal Officer
Ms. Gry Husby Larsen
SVP of Global Marketing & US Commercialization
Ms. Jennifer Zonderman
Executive VP of Strategic Partnerships and GM of EMEA & APAC
Mr. Nis Kruse
Show More
President & CEO of BioPorto Inc.
Mr. Jeffrey N. Haas
Show Less

See Also

Discover More
What is the Intrinsic Value of one BIOPOR stock?

The intrinsic value of one BIOPOR stock under the Base Case scenario is 1.257 DKK.

Is BIOPOR stock undervalued or overvalued?

Compared to the current market price of 1.624 DKK, Bioporto A/S is Overvalued by 23%.

Back to Top